This technology is a method for stimulating hematopoietic stem cell (HSC) and progenitor cell regeneration to improve bone marrow transplants and other regenerative therapies.
Hematopoietic stem cells (HSCs) and progenitors are cells that regenerate the blood and immune systems and are used for their self-renewal properties to replenish the hematopoietic system after injury or during transplantation. HSCs used for serial transplantation gradually lose their self-renewal and blood cell output with each round of transplantation. Currently, there are no methods to regulate or control the efficiency of self-renewal in HSCs and progenitors.
This technology identifies the unique role that peroxisomes, metabolic organelles that break down long-chain fatty acids, play in hematopoietic stem cell (HSC) regulation. Inhibition of this metabolic process results in extensive self-renewal in HSCs and progenitors. Deleting a key protein in this pathway results in greater multilineage reconstitution and a higher contribution of HSCs and progenitors in mice. By controlling this pathway, this technology has the potential to augment the effectiveness of HSCs in bone marrow transplantation and other regenerative therapies.
This technology has been validated with mouse models with no adverse effects.
Patent Pending
IR CU25234
Licensing Contact: Kristin Neuman